| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA551: Lenvatinib for untreated advanced hepatocellular carcinoma |
|
Medicine details |
|
| Medicine name | lenvatinib (Lenvima®) |
| Formulation | 4 mg and 10 mg capsule |
| Reference number | 2203 |
| Indication | Monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy |
| Company | Eisai Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 21/08/2019 |
| NICE guidance | TA551: Lenvatinib for untreated advanced hepatocellular carcinoma |